Ceftriax (ceftriaxone) powder for injected (5 vials/1g)

Active ingredient: ceftriaxone

Release form: Powder for injections

Description

Crystalline powder of white or yellowish color. Weakly hygroscopic.

Compound

5  vials contain the active ingredient:

ceftriaxone sodium salt sterile in terms of ceftriaxone – 1.0 g. each vial

Pharmacological properties

Ceftriaxone is a third-generation cephalosporin antibiotic for parenteral administration with a wide spectrum of antimicrobial activity, high activity (especially in infections caused by penicillinase-producing microorganisms) and prolonged action. It has a bactericidal effect by inhibiting the synthesis of the bacterial cell wall. Ceftriaxone acetylates membrane-bound ¢ linked transpeptidases, thus disrupting peptidoglycan cross-linking, which is essential for cell wall strength and rigidity. Ceftriaxone is active against gram-positive aerobic bacteria: Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans; gram-negative aerobic: Enterobacteraerogenes, Enterobacter cloacae, Escherichia salts, Haemorhilus influenzae, Haemorhilus parainfluenzae, Klebsiella spp. (Including K. pneumoniae), Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae, N. meningitidis, Proteus mirabilis, Proteus vulgaris, Serratia spp. (Including Serratia marcessens), Acinetobacter calcoaceticus; Peptostreptococcus spp., Basteroides fragilis, Clostridium spp. (Except Clostridium difficile), Pseudomonas aeruginosa. It has in vitro activity against most strains of such microorganisms: Providencia spp., Basteroides bivius, Basteroides melaninogenicus, Salmonella spp. (Including Salmonella turhi), Shigella spp., Streptococcus agalactiae, Providencia rettgeri, Citrobacter freundii. Neisseria gonorrhoeae, N. meningitidis, Proteus mirabilis, Proteus vulgaris, Serratia spp. (Including Serratia marcessens), Acinetobacter calcoaceticus; Peptostreptococcus spp., Basteroides fragilis, Clostridium spp. (Except Clostridium difficile), Pseudomonas aeruginosa. It has in vitro activity against most strains of such microorganisms: Providencia spp., Basteroides bivius, Basteroides melaninogenicus, Salmonella spp. (Including Salmonella turhi), Shigella spp., Streptococcus agalactiae, Providencia rettgeri, Citrobacter freundii. Neisseria gonorrhoeae, N. meningitidis, Proteus mirabilis, Proteus vulgaris, Serratia spp. (Including Serratia marcessens), Acinetobacter calcoaceticus; Peptostreptococcus spp., Basteroides fragilis, Clostridium spp. (Except Clostridium difficile), Pseudomonas aeruginosa. It has in vitro activity against most strains of such microorganisms: Providencia spp., Basteroides bivius, Basteroides melaninogenicus, Salmonella spp. (Including Salmonella turhi), Shigella spp., Streptococcus agalactiae, Providencia rettgeri, Citrobacter freundii. It has in vitro activity against most strains of such microorganisms: Providencia spp., Basteroides bivius, Basteroides melaninogenicus, Salmonella spp. (Including Salmonella turhi), Shigella spp., Streptococcus agalactiae, Providencia rettgeri, Citrobacter freundii. It has in vitro activity against most strains of such microorganisms: Providencia spp., Basteroides bivius, Basteroides melaninogenicus, Salmonella spp. (Including Salmonella turhi), Shigella spp., Streptococcus agalactiae, Providencia rettgeri, Citrobacter freundii.

Application

Treatment of dogs and cats with otitis, sepsis, meningitis, as well as diseases of the respiratory and genitourinary system, skin and soft tissues, bones caused by microorganisms sensitive to ceftriaxone. It is used to prevent postoperative complications.

Dosage

For administration to dogs, the contents of one vial are dissolved in 3.6 ml of a 1% lidocaine solution or 0.25% – 0.5% novocaine solution, or in 3.6 ml of sterile water for injection. 1 ml of the solution thus prepared contains about 250 mg of ceftriaxone for a 1.0 g vial.

For administration to cats, the contents of one vial are dissolved in 3.6 ml of a 0.25% -0.5% novocaine solution or 3.6 ml of sterile water for injection. When used in cats, do not dilute the drug with lidocaine. 1 ml of the solution thus prepared contains about 250 mg of ceftriaxone for a 1.0 g vial.

For jet administration, the contents of the vial are dissolved in 9.6 ml of sterile water for injection or 0.9% sodium chloride solution, or 5% glucose solution. 1 ml of the solution thus prepared contains about 100 mg of ceftriaxone for a 1.0 g vial.

For intravenous drip, the contents of the vial are dissolved in 100-250 ml of 0.9% sodium chloride solution, or 5% glucose solution. The injection is carried out within 20-30 minutes (injection rate 60-80 drops per 1 minute).

The daily dose is 20-40 mg of ceftriaxone per 1 kg of body weight. If necessary, the frequency of use can be increased up to 2 times a day with a dosage of 10-20 mg of ceftriaxone per 1 kg of body weight. The drug is used from 5 to 10 days, depending on the form and severity of the disease.

*Kilograms to a Pounds conversion table

Contraindications

Hypersensitivity to a group of cephalosporins and other b-lactam antibiotics.

Do not administer to animals with renal or hepatic insufficiency. Do not administer to animals during pregnancy.

Warning

Gallbladder stones may form when dogs are treated with high doses of ceftriaxone. In the case of hypersensitivity to lidocaine, it is not recommended to use its 1% solution as a solvent.